Novo Nordisk secures EU regulatory approval to streamline Wegovy distribution, paving way for broader home delivery

Novo Nordisk has recently announced that the European Medicines Agency has approved a change to Wegovy’s product information that removes the requirement for full cold chain logistics during the final stage of delivery to patients. Wegovy injection can now be transported at temperatures of up to 30°C for up to 48 hours, making it the only GLP-1 weight management drug in Europe with this flexibility.

Until now, Wegovy distribution across Europe required continuous refrigeration from the point of manufacture all the way through to the patient. That placed significant logistical and cost burdens on pharmacies and distribution partners, particularly those operating online or direct-to-patient models. The EMA’s approval changes only the final leg of that journey, from the pharmacy to the patient’s door, while manufacturing and wholesale distribution remain subject to cold chain requirements.

The practical implications are meaningful. Reduced dependence on specialist cold packaging is expected to lower distribution costs, reduce packaging volume and weight, and simplify operations for pharmacy and eHealth partners across Europe. For online pharmacies and telehealth platforms in particular, the change could make it substantially easier and more economical to offer home delivery of Wegovy at scale.

Mike Doustdar, CEO of Novo Nordisk, tied the regulatory change to a broader access and stigma argument. “People with obesity using prescription medicine may also face stigma, and we are therefore excited about the opportunity to reduce distribution complexity while further enabling discrete home delivery options,” he said. The ability to receive a weight management medicine through standard home delivery channels, without any visible cold chain packaging, is likely to matter to a meaningful proportion of patients.

The Bigger Commercial Picture

The approval lands at a pivotal moment for Novo Nordisk in Europe. The company is competing with Eli Lilly’s tirzepatide for market share in the injectable obesity space and is simultaneously awaiting a regulatory decision on its Wegovy pill in the EU, expected later in 2026. Anything that lowers the cost and complexity of getting Wegovy injections into patients’ hands strengthens Novo’s commercial position in the near term.

The change applies only to the injectable formulation of Wegovy. The Wegovy pill, approved in the US, requires no refrigeration at all and remains under EMA review for the European market.

---

---

Related Topics and Keywords

Biopharma, COLDCHAIN, EMA, glp1, LifeSciences, NovoNordisk, NVO, ObesityTreatment, RegulatoryApproval, Wegovy®